Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
HIV Infections | 118 | 2024 | 17159 | 2.930 |
Why?
|
Anti-HIV Agents | 55 | 2024 | 4492 | 2.410 |
Why?
|
Reverse Transcriptase Inhibitors | 22 | 2022 | 618 | 1.600 |
Why?
|
Benzoxazines | 23 | 2015 | 309 | 1.590 |
Why?
|
HIV-1 | 49 | 2024 | 6850 | 1.470 |
Why?
|
Antiretroviral Therapy, Highly Active | 24 | 2019 | 1894 | 1.000 |
Why?
|
Anti-Retroviral Agents | 15 | 2023 | 1780 | 0.960 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 11 | 2024 | 3333 | 0.900 |
Why?
|
Ritonavir | 9 | 2016 | 328 | 0.890 |
Why?
|
Oxidoreductases, N-Demethylating | 4 | 2013 | 110 | 0.810 |
Why?
|
Aryl Hydrocarbon Hydroxylases | 4 | 2013 | 253 | 0.760 |
Why?
|
Viral Load | 27 | 2024 | 3323 | 0.760 |
Why?
|
Plaque, Atherosclerotic | 9 | 2024 | 1520 | 0.760 |
Why?
|
HIV Protease Inhibitors | 6 | 2016 | 432 | 0.760 |
Why?
|
Quinolines | 7 | 2024 | 759 | 0.730 |
Why?
|
Dideoxynucleosides | 9 | 2015 | 132 | 0.720 |
Why?
|
Cardiovascular Diseases | 21 | 2024 | 15740 | 0.720 |
Why?
|
Alkynes | 23 | 2015 | 313 | 0.650 |
Why?
|
Drug Resistance, Viral | 15 | 2023 | 859 | 0.640 |
Why?
|
Cyclopropanes | 23 | 2015 | 431 | 0.620 |
Why?
|
RNA, Viral | 19 | 2024 | 2837 | 0.610 |
Why?
|
Methotrexate | 5 | 2024 | 1717 | 0.590 |
Why?
|
Randomized Controlled Trials as Topic | 16 | 2024 | 10340 | 0.540 |
Why?
|
Coronary Artery Disease | 10 | 2024 | 6661 | 0.520 |
Why?
|
CD4 Lymphocyte Count | 20 | 2024 | 2569 | 0.510 |
Why?
|
Glucuronosyltransferase | 2 | 2012 | 130 | 0.510 |
Why?
|
Acquired Immunodeficiency Syndrome | 8 | 2015 | 2197 | 0.500 |
Why?
|
Unsafe Sex | 1 | 2016 | 213 | 0.490 |
Why?
|
Cyclohexanes | 4 | 2016 | 152 | 0.480 |
Why?
|
Oxazines | 6 | 2006 | 341 | 0.440 |
Why?
|
HIV | 11 | 2023 | 1579 | 0.420 |
Why?
|
HIV Seropositivity | 3 | 2020 | 955 | 0.420 |
Why?
|
Nevirapine | 5 | 2013 | 273 | 0.370 |
Why?
|
Cytochrome P-450 CYP3A | 1 | 2010 | 114 | 0.350 |
Why?
|
Triazoles | 4 | 2016 | 904 | 0.330 |
Why?
|
Treatment Failure | 16 | 2021 | 2646 | 0.320 |
Why?
|
Drug Therapy, Combination | 16 | 2016 | 6499 | 0.310 |
Why?
|
Research Subjects | 2 | 2020 | 249 | 0.310 |
Why?
|
Brachial Artery | 2 | 2020 | 368 | 0.300 |
Why?
|
Oligopeptides | 2 | 2014 | 1188 | 0.300 |
Why?
|
Double-Blind Method | 22 | 2024 | 12412 | 0.290 |
Why?
|
Cytomegalovirus Infections | 2 | 2024 | 831 | 0.280 |
Why?
|
Atherosclerosis | 5 | 2024 | 3524 | 0.270 |
Why?
|
Male | 95 | 2024 | 359413 | 0.270 |
Why?
|
Female | 99 | 2024 | 391011 | 0.260 |
Why?
|
Middle Aged | 68 | 2024 | 220175 | 0.260 |
Why?
|
Clinical Trials, Phase III as Topic | 3 | 2019 | 859 | 0.250 |
Why?
|
Humans | 130 | 2024 | 760261 | 0.240 |
Why?
|
Multicenter Studies as Topic | 5 | 2020 | 1723 | 0.230 |
Why?
|
Adult | 73 | 2024 | 219847 | 0.230 |
Why?
|
Pregnancy Complications, Infectious | 6 | 2016 | 2127 | 0.220 |
Why?
|
HIV Integrase Inhibitors | 2 | 2023 | 165 | 0.210 |
Why?
|
HIV Integrase | 1 | 2023 | 121 | 0.200 |
Why?
|
Medication Adherence | 6 | 2014 | 2163 | 0.200 |
Why?
|
Lipoproteins, LDL | 3 | 2024 | 641 | 0.200 |
Why?
|
Anti-Inflammatory Agents | 3 | 2022 | 1799 | 0.190 |
Why?
|
Pyridines | 2 | 2014 | 2877 | 0.190 |
Why?
|
HIV Long-Term Survivors | 2 | 2020 | 121 | 0.190 |
Why?
|
Inflammation | 8 | 2024 | 10757 | 0.190 |
Why?
|
CD4-CD8 Ratio | 2 | 2020 | 114 | 0.180 |
Why?
|
Primary Prevention | 4 | 2023 | 1207 | 0.180 |
Why?
|
Bone Density | 5 | 2017 | 3528 | 0.170 |
Why?
|
Viremia | 2 | 2014 | 708 | 0.170 |
Why?
|
Zidovudine | 7 | 2010 | 624 | 0.150 |
Why?
|
Models, Statistical | 3 | 2022 | 5073 | 0.150 |
Why?
|
Indinavir | 4 | 2010 | 73 | 0.150 |
Why?
|
Research Design | 2 | 2022 | 6181 | 0.150 |
Why?
|
Pharmacogenetics | 3 | 2011 | 680 | 0.150 |
Why?
|
Infectious Disease Transmission, Vertical | 3 | 2016 | 1349 | 0.140 |
Why?
|
Plasma | 3 | 2015 | 584 | 0.140 |
Why?
|
Treatment Outcome | 25 | 2019 | 64947 | 0.140 |
Why?
|
Lamivudine | 6 | 2007 | 363 | 0.140 |
Why?
|
Osteoporosis | 2 | 2017 | 1600 | 0.140 |
Why?
|
Immunosuppressive Agents | 2 | 2020 | 4168 | 0.140 |
Why?
|
Adenine | 3 | 2014 | 976 | 0.140 |
Why?
|
Endothelium | 1 | 2019 | 764 | 0.140 |
Why?
|
Vasodilation | 1 | 2020 | 964 | 0.140 |
Why?
|
Ultrasonography, Doppler | 1 | 2018 | 466 | 0.140 |
Why?
|
HIV Seronegativity | 2 | 2020 | 208 | 0.130 |
Why?
|
Body Composition | 3 | 2016 | 2418 | 0.130 |
Why?
|
Nelfinavir | 3 | 2004 | 68 | 0.130 |
Why?
|
Amino Acids | 2 | 2020 | 1715 | 0.130 |
Why?
|
Hair | 1 | 2019 | 492 | 0.130 |
Why?
|
Calcium Carbonate | 1 | 2015 | 62 | 0.130 |
Why?
|
Coronary Disease | 1 | 2010 | 5993 | 0.120 |
Why?
|
Immunomodulation | 1 | 2019 | 547 | 0.120 |
Why?
|
Condoms | 1 | 2016 | 315 | 0.120 |
Why?
|
Risk Factors | 19 | 2024 | 74269 | 0.120 |
Why?
|
Gender Identity | 1 | 2020 | 699 | 0.120 |
Why?
|
Calcifediol | 1 | 2015 | 161 | 0.120 |
Why?
|
Sexual Partners | 2 | 2016 | 750 | 0.120 |
Why?
|
Vitamin D | 2 | 2019 | 3293 | 0.120 |
Why?
|
Child Mortality | 1 | 2016 | 206 | 0.110 |
Why?
|
Abdominal Fat | 1 | 2016 | 223 | 0.110 |
Why?
|
Computer Simulation | 1 | 2007 | 6210 | 0.110 |
Why?
|
Infant Mortality | 2 | 2016 | 756 | 0.110 |
Why?
|
Polymorphism, Single Nucleotide | 4 | 2015 | 15766 | 0.110 |
Why?
|
Quality of Life | 4 | 2007 | 13300 | 0.110 |
Why?
|
Inhibitory Concentration 50 | 2 | 2013 | 465 | 0.110 |
Why?
|
Nucleosides | 2 | 2022 | 131 | 0.110 |
Why?
|
HIV Reverse Transcriptase | 3 | 2010 | 212 | 0.110 |
Why?
|
Coronary Angiography | 5 | 2024 | 4560 | 0.100 |
Why?
|
Botswana | 5 | 2016 | 1042 | 0.100 |
Why?
|
Jaundice | 1 | 2012 | 97 | 0.100 |
Why?
|
Carotid Arteries | 2 | 2015 | 951 | 0.100 |
Why?
|
Genotype | 7 | 2012 | 12959 | 0.100 |
Why?
|
Lipoproteins, HDL | 1 | 2016 | 667 | 0.100 |
Why?
|
Young Adult | 17 | 2020 | 58673 | 0.100 |
Why?
|
Glomerular Filtration Rate | 1 | 2020 | 2178 | 0.100 |
Why?
|
Myocardial Infarction | 2 | 2023 | 11891 | 0.100 |
Why?
|
Deoxycytidine | 2 | 2014 | 872 | 0.100 |
Why?
|
Multivariate Analysis | 3 | 2012 | 12156 | 0.100 |
Why?
|
Hyperlipidemias | 1 | 2016 | 782 | 0.100 |
Why?
|
Bilirubin | 1 | 2012 | 438 | 0.090 |
Why?
|
Survival Analysis | 2 | 2019 | 10185 | 0.090 |
Why?
|
Central Nervous System Diseases | 2 | 2005 | 521 | 0.090 |
Why?
|
Health Resources | 2 | 2014 | 936 | 0.090 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2014 | 661 | 0.090 |
Why?
|
Immunologic Factors | 1 | 2019 | 1589 | 0.090 |
Why?
|
Genes, MHC Class I | 1 | 2010 | 240 | 0.090 |
Why?
|
Antiviral Agents | 2 | 2015 | 3061 | 0.090 |
Why?
|
Models, Biological | 2 | 2010 | 9468 | 0.090 |
Why?
|
Premature Birth | 2 | 2012 | 1771 | 0.090 |
Why?
|
Polymorphism, Genetic | 4 | 2013 | 4286 | 0.090 |
Why?
|
Patient Selection | 2 | 2020 | 4276 | 0.080 |
Why?
|
Clinical Trials as Topic | 3 | 2016 | 8058 | 0.080 |
Why?
|
Vaccination | 1 | 2022 | 3360 | 0.080 |
Why?
|
Stillbirth | 1 | 2012 | 365 | 0.080 |
Why?
|
Cohort Studies | 11 | 2021 | 41317 | 0.080 |
Why?
|
HLA-B Antigens | 1 | 2010 | 331 | 0.080 |
Why?
|
Carotid Artery Diseases | 1 | 2015 | 881 | 0.080 |
Why?
|
Cytomegalovirus | 2 | 2024 | 756 | 0.080 |
Why?
|
Comorbidity | 2 | 2020 | 10552 | 0.080 |
Why?
|
Attitude to Health | 2 | 2016 | 2028 | 0.080 |
Why?
|
Genetic Variation | 3 | 2012 | 6540 | 0.080 |
Why?
|
Homosexuality, Male | 1 | 2016 | 1269 | 0.080 |
Why?
|
Epistasis, Genetic | 1 | 2011 | 350 | 0.080 |
Why?
|
Chi-Square Distribution | 2 | 2013 | 3466 | 0.080 |
Why?
|
Endothelium, Vascular | 1 | 2020 | 4437 | 0.080 |
Why?
|
Prospective Studies | 13 | 2022 | 54263 | 0.080 |
Why?
|
Cardiomyopathies | 1 | 2020 | 1945 | 0.080 |
Why?
|
T-Lymphocyte Subsets | 1 | 2016 | 1811 | 0.080 |
Why?
|
Aged | 18 | 2023 | 168995 | 0.080 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2023 | 4355 | 0.070 |
Why?
|
Bone Density Conservation Agents | 1 | 2015 | 794 | 0.070 |
Why?
|
Antibodies, Viral | 3 | 2024 | 3145 | 0.070 |
Why?
|
Half-Life | 2 | 2005 | 652 | 0.070 |
Why?
|
Tuberculosis, Pulmonary | 1 | 2014 | 832 | 0.070 |
Why?
|
Prevalence | 3 | 2022 | 15687 | 0.070 |
Why?
|
Birth Weight | 2 | 2012 | 2094 | 0.070 |
Why?
|
Cross-Sectional Studies | 7 | 2023 | 25928 | 0.070 |
Why?
|
Purine Nucleosides | 1 | 2006 | 30 | 0.070 |
Why?
|
Dioxolanes | 1 | 2006 | 25 | 0.070 |
Why?
|
Drug Administration Schedule | 5 | 2014 | 4900 | 0.070 |
Why?
|
Renal Insufficiency, Chronic | 1 | 2020 | 2296 | 0.070 |
Why?
|
Disease Transmission, Infectious | 1 | 2011 | 558 | 0.060 |
Why?
|
HIV Fusion Inhibitors | 1 | 2006 | 82 | 0.060 |
Why?
|
Body Mass Index | 5 | 2023 | 12901 | 0.060 |
Why?
|
Cholesterol | 1 | 2014 | 2925 | 0.060 |
Why?
|
United States | 8 | 2023 | 72363 | 0.060 |
Why?
|
Antigen Presentation | 1 | 2010 | 1254 | 0.060 |
Why?
|
Endpoint Determination | 2 | 2013 | 597 | 0.060 |
Why?
|
Treatment Refusal | 1 | 2007 | 430 | 0.060 |
Why?
|
Calcium | 1 | 2017 | 5726 | 0.060 |
Why?
|
Adolescent | 10 | 2020 | 87747 | 0.060 |
Why?
|
Follow-Up Studies | 5 | 2016 | 39254 | 0.060 |
Why?
|
HIV Envelope Protein gp41 | 1 | 2006 | 303 | 0.060 |
Why?
|
Time Factors | 9 | 2019 | 40133 | 0.050 |
Why?
|
Bone Resorption | 2 | 2019 | 720 | 0.050 |
Why?
|
Gestational Age | 1 | 2011 | 3564 | 0.050 |
Why?
|
Thailand | 2 | 2014 | 289 | 0.050 |
Why?
|
Immunophenotyping | 2 | 2019 | 1870 | 0.050 |
Why?
|
C-Reactive Protein | 2 | 2013 | 3822 | 0.050 |
Why?
|
South Africa | 2 | 2021 | 1821 | 0.050 |
Why?
|
1-Alkyl-2-acetylglycerophosphocholine Esterase | 1 | 2023 | 129 | 0.050 |
Why?
|
Sample Size | 1 | 2006 | 840 | 0.050 |
Why?
|
Dietary Supplements | 1 | 2015 | 3389 | 0.050 |
Why?
|
Genome-Wide Association Study | 4 | 2015 | 12602 | 0.050 |
Why?
|
Coronary Vessels | 2 | 2023 | 3112 | 0.050 |
Why?
|
Cholesterol, LDL | 2 | 2024 | 2422 | 0.050 |
Why?
|
Risk Assessment | 4 | 2022 | 24086 | 0.050 |
Why?
|
Drug Therapy | 2 | 2015 | 504 | 0.050 |
Why?
|
Immunoglobulin G | 2 | 2024 | 4546 | 0.050 |
Why?
|
Africa | 2 | 2015 | 707 | 0.050 |
Why?
|
Floxuridine | 1 | 2000 | 43 | 0.050 |
Why?
|
Research | 1 | 2010 | 1973 | 0.050 |
Why?
|
AIDS-Associated Nephropathy | 1 | 2020 | 34 | 0.050 |
Why?
|
Patient Compliance | 3 | 2007 | 2689 | 0.050 |
Why?
|
Statistical Distributions | 1 | 2020 | 63 | 0.050 |
Why?
|
Mutation, Missense | 1 | 2010 | 2563 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 3 | 2019 | 6545 | 0.040 |
Why?
|
Mutation | 6 | 2021 | 29950 | 0.040 |
Why?
|
North America | 1 | 2024 | 1282 | 0.040 |
Why?
|
Infusion Pumps, Implantable | 1 | 2000 | 157 | 0.040 |
Why?
|
Least-Squares Analysis | 1 | 2000 | 369 | 0.040 |
Why?
|
Adipose Tissue | 2 | 2023 | 3293 | 0.040 |
Why?
|
Integrases | 1 | 2022 | 516 | 0.040 |
Why?
|
Parathyroid Hormone | 2 | 2017 | 1797 | 0.040 |
Why?
|
Genetic Testing | 1 | 2012 | 3530 | 0.040 |
Why?
|
AIDS Serodiagnosis | 1 | 2020 | 216 | 0.040 |
Why?
|
Placebos | 2 | 2016 | 1672 | 0.040 |
Why?
|
Proteomics | 2 | 2023 | 3810 | 0.040 |
Why?
|
Muscles | 1 | 2024 | 1581 | 0.040 |
Why?
|
Proportional Hazards Models | 4 | 2016 | 12532 | 0.040 |
Why?
|
Mood Disorders | 1 | 2005 | 1123 | 0.040 |
Why?
|
Cost-Benefit Analysis | 2 | 2012 | 5507 | 0.040 |
Why?
|
Pilot Projects | 4 | 2015 | 8553 | 0.040 |
Why?
|
Pregnancy | 7 | 2016 | 29725 | 0.040 |
Why?
|
Lipids | 3 | 2016 | 3336 | 0.040 |
Why?
|
Blood Proteins | 1 | 2023 | 1172 | 0.040 |
Why?
|
DNA, Viral | 1 | 2024 | 2195 | 0.040 |
Why?
|
Blood Glucose | 3 | 2021 | 6375 | 0.040 |
Why?
|
Transsexualism | 1 | 2020 | 177 | 0.040 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2000 | 640 | 0.030 |
Why?
|
Biological Availability | 1 | 2017 | 395 | 0.030 |
Why?
|
Predictive Value of Tests | 3 | 2020 | 15273 | 0.030 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2018 | 418 | 0.030 |
Why?
|
India | 2 | 2014 | 2346 | 0.030 |
Why?
|
Drug Interactions | 1 | 2020 | 1426 | 0.030 |
Why?
|
Case-Control Studies | 4 | 2020 | 22041 | 0.030 |
Why?
|
Guideline Adherence | 1 | 2005 | 2283 | 0.030 |
Why?
|
Tissue Distribution | 1 | 2019 | 2262 | 0.030 |
Why?
|
Drug Combinations | 2 | 2014 | 2024 | 0.030 |
Why?
|
Therapeutic Equivalency | 1 | 2014 | 136 | 0.030 |
Why?
|
Longitudinal Studies | 3 | 2015 | 14482 | 0.030 |
Why?
|
Bone Remodeling | 1 | 2017 | 580 | 0.030 |
Why?
|
Linear Models | 2 | 2016 | 5876 | 0.030 |
Why?
|
International Cooperation | 1 | 2020 | 1436 | 0.030 |
Why?
|
Asia | 1 | 2015 | 618 | 0.030 |
Why?
|
Peptide Fragments | 1 | 2006 | 5120 | 0.030 |
Why?
|
Developing Countries | 2 | 2016 | 2880 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2019 | 10829 | 0.030 |
Why?
|
Malawi | 1 | 2014 | 301 | 0.030 |
Why?
|
Pelvic Bones | 1 | 2015 | 271 | 0.030 |
Why?
|
Metabolic Clearance Rate | 1 | 2013 | 361 | 0.030 |
Why?
|
Intention to Treat Analysis | 1 | 2014 | 422 | 0.030 |
Why?
|
Osteoprotegerin | 1 | 2013 | 177 | 0.030 |
Why?
|
Minority Groups | 1 | 2020 | 1199 | 0.030 |
Why?
|
Pyridazines | 1 | 2014 | 200 | 0.030 |
Why?
|
Triglycerides | 1 | 2020 | 2476 | 0.030 |
Why?
|
Sex Characteristics | 1 | 2023 | 2627 | 0.030 |
Why?
|
Consensus | 1 | 2022 | 3106 | 0.030 |
Why?
|
Protease Inhibitors | 1 | 2016 | 755 | 0.030 |
Why?
|
Birth Certificates | 1 | 2011 | 70 | 0.020 |
Why?
|
Data Interpretation, Statistical | 1 | 2022 | 2696 | 0.020 |
Why?
|
Infant, Newborn | 4 | 2013 | 26168 | 0.020 |
Why?
|
National Institute of Allergy and Infectious Diseases (U.S.) | 1 | 2011 | 62 | 0.020 |
Why?
|
RANK Ligand | 1 | 2013 | 318 | 0.020 |
Why?
|
Meningioma | 1 | 2000 | 1220 | 0.020 |
Why?
|
Metabolism, Inborn Errors | 1 | 2013 | 285 | 0.020 |
Why?
|
Hypertension | 1 | 2011 | 8595 | 0.020 |
Why?
|
Meningeal Neoplasms | 1 | 2000 | 1248 | 0.020 |
Why?
|
Self Report | 1 | 2022 | 3707 | 0.020 |
Why?
|
Chemoprevention | 1 | 2013 | 326 | 0.020 |
Why?
|
Disease Progression | 3 | 2014 | 13505 | 0.020 |
Why?
|
Receptors, Drug | 1 | 2011 | 157 | 0.020 |
Why?
|
Polymerase Chain Reaction | 2 | 2010 | 6067 | 0.020 |
Why?
|
HLA-C Antigens | 1 | 2010 | 147 | 0.020 |
Why?
|
Oxidation-Reduction | 1 | 2016 | 2222 | 0.020 |
Why?
|
HLA-A Antigens | 1 | 2010 | 225 | 0.020 |
Why?
|
Potassium Channels, Inwardly Rectifying | 1 | 2011 | 144 | 0.020 |
Why?
|
Biometry | 1 | 2013 | 559 | 0.020 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2020 | 3764 | 0.020 |
Why?
|
HIV Antigens | 1 | 2010 | 325 | 0.020 |
Why?
|
American Heart Association | 1 | 2014 | 1081 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2015 | 4554 | 0.020 |
Why?
|
Tanzania | 1 | 2014 | 1379 | 0.020 |
Why?
|
Absorptiometry, Photon | 1 | 2015 | 1731 | 0.020 |
Why?
|
Nitriles | 1 | 2014 | 955 | 0.020 |
Why?
|
Spouses | 1 | 2011 | 279 | 0.020 |
Why?
|
Infant, Small for Gestational Age | 1 | 2011 | 460 | 0.020 |
Why?
|
Dreams | 1 | 2009 | 146 | 0.020 |
Why?
|
Communication | 1 | 2022 | 3846 | 0.020 |
Why?
|
Muscle, Skeletal | 1 | 2023 | 4923 | 0.020 |
Why?
|
Gene Dosage | 1 | 2012 | 1218 | 0.020 |
Why?
|
Drug Resistance, Multiple, Viral | 1 | 2008 | 53 | 0.020 |
Why?
|
Breast Feeding | 1 | 2016 | 1356 | 0.020 |
Why?
|
Sensitivity and Specificity | 2 | 2015 | 14656 | 0.020 |
Why?
|
ATP-Binding Cassette Transporters | 1 | 2011 | 563 | 0.020 |
Why?
|
Cytokines | 1 | 2022 | 7345 | 0.020 |
Why?
|
Adiponectin | 1 | 2013 | 1115 | 0.020 |
Why?
|
Sex Factors | 2 | 2011 | 10530 | 0.020 |
Why?
|
Health Status | 1 | 2020 | 4081 | 0.020 |
Why?
|
Clinical Protocols | 1 | 2012 | 1439 | 0.020 |
Why?
|
Cell Proliferation | 1 | 2022 | 10434 | 0.020 |
Why?
|
Quality-Adjusted Life Years | 1 | 2012 | 1724 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2016 | 5873 | 0.020 |
Why?
|
Diabetes Complications | 1 | 2013 | 1342 | 0.020 |
Why?
|
Antigens, CD | 1 | 2016 | 4002 | 0.020 |
Why?
|
Withholding Treatment | 1 | 2010 | 613 | 0.020 |
Why?
|
Weight Gain | 1 | 2016 | 2347 | 0.020 |
Why?
|
Amino Acid Substitution | 1 | 2010 | 1737 | 0.020 |
Why?
|
Liver Diseases | 1 | 2014 | 1301 | 0.020 |
Why?
|
Leptin | 1 | 2013 | 1590 | 0.020 |
Why?
|
HIV Antibodies | 1 | 2011 | 1300 | 0.020 |
Why?
|
Liver Neoplasms | 1 | 2000 | 4317 | 0.020 |
Why?
|
Sulfonamides | 1 | 2014 | 1973 | 0.010 |
Why?
|
Stavudine | 1 | 2004 | 84 | 0.010 |
Why?
|
Statistics, Nonparametric | 1 | 2010 | 2852 | 0.010 |
Why?
|
Diet | 1 | 2022 | 8008 | 0.010 |
Why?
|
Haplotypes | 1 | 2010 | 2764 | 0.010 |
Why?
|
Counseling | 1 | 2012 | 1550 | 0.010 |
Why?
|
Age Factors | 1 | 2020 | 18415 | 0.010 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2002 | 5248 | 0.010 |
Why?
|
Interleukin-6 | 1 | 2013 | 3207 | 0.010 |
Why?
|
Genetic Association Studies | 1 | 2012 | 2716 | 0.010 |
Why?
|
Gene Frequency | 1 | 2010 | 3605 | 0.010 |
Why?
|
Pandemics | 1 | 2023 | 8621 | 0.010 |
Why?
|
Protein Conformation | 1 | 2010 | 3969 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2020 | 15827 | 0.010 |
Why?
|
Brain | 1 | 2009 | 26912 | 0.010 |
Why?
|
Cytochrome P-450 Enzyme System | 1 | 2004 | 412 | 0.010 |
Why?
|
Pyrimidines | 1 | 2014 | 3011 | 0.010 |
Why?
|
Lactic Acid | 1 | 2007 | 1132 | 0.010 |
Why?
|
Kidney Failure, Chronic | 1 | 2014 | 2469 | 0.010 |
Why?
|
Contrast Media | 1 | 2014 | 5301 | 0.010 |
Why?
|
Colorectal Neoplasms | 1 | 2000 | 6855 | 0.010 |
Why?
|
Models, Molecular | 1 | 2010 | 5429 | 0.010 |
Why?
|
Algorithms | 1 | 2000 | 13967 | 0.010 |
Why?
|
Ultrasonography | 1 | 2013 | 5960 | 0.010 |
Why?
|
Area Under Curve | 1 | 2004 | 1635 | 0.010 |
Why?
|
Genome, Human | 1 | 2012 | 4416 | 0.010 |
Why?
|
Alleles | 1 | 2010 | 6900 | 0.010 |
Why?
|
Brain Neoplasms | 1 | 2000 | 8984 | 0.010 |
Why?
|
Risk | 1 | 2011 | 9629 | 0.010 |
Why?
|
Computational Biology | 1 | 2011 | 3504 | 0.010 |
Why?
|
Immunity, Innate | 1 | 2010 | 3046 | 0.010 |
Why?
|
Retrospective Studies | 3 | 2012 | 80301 | 0.010 |
Why?
|
Incidence | 1 | 2016 | 21378 | 0.010 |
Why?
|
Lung Neoplasms | 1 | 2002 | 13249 | 0.010 |
Why?
|
Regression Analysis | 1 | 2007 | 6361 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2014 | 7468 | 0.010 |
Why?
|
Software | 1 | 2011 | 4420 | 0.010 |
Why?
|
Neuropsychological Tests | 1 | 2009 | 7016 | 0.010 |
Why?
|
Blotting, Western | 1 | 2004 | 5039 | 0.010 |
Why?
|
Logistic Models | 1 | 2010 | 13311 | 0.010 |
Why?
|
Anxiety | 1 | 2009 | 4532 | 0.010 |
Why?
|
Neoplasms | 2 | 2014 | 22066 | 0.010 |
Why?
|
Infant | 1 | 2016 | 36030 | 0.010 |
Why?
|
Liver | 1 | 2010 | 7512 | 0.010 |
Why?
|
Child | 1 | 2022 | 79758 | 0.010 |
Why?
|
Child, Preschool | 1 | 2016 | 42034 | 0.010 |
Why?
|
Insulin Resistance | 1 | 2007 | 3960 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2020 | 36247 | 0.010 |
Why?
|
Aged, 80 and over | 2 | 2012 | 58947 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2006 | 12762 | 0.010 |
Why?
|
Depression | 1 | 2009 | 8033 | 0.010 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2014 | 12281 | 0.010 |
Why?
|
Combined Modality Therapy | 1 | 2000 | 8551 | 0.000 |
Why?
|
Phenotype | 1 | 2004 | 16543 | 0.000 |
Why?
|
Reproducibility of Results | 1 | 2000 | 20048 | 0.000 |
Why?
|